Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis
May 30, 2023 09:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s Program
May 22, 2023 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
May 19, 2023 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors
May 18, 2023 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md. and PRAGUE, Czech Republic, May 18, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ORGS) (“Orgenesis”), a global biotech company working to unlock the full potential of cell and gene therapies...
Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy
May 10, 2023 16:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary
May 10, 2023 10:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy Manufacturing
April 25, 2023 08:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., April 25, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022
March 21, 2023 08:00 ET
|
Orgenesis Inc.
Rapid growth reflects progress of POCare Platform Orgenesis to host conference call today at 11:00 AM ET GERMANTOWN, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS)...
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
March 17, 2023 09:00 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California
March 16, 2023 07:30 ET
|
Orgenesis Inc.
GERMANTOWN, Md., March 16, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...